Bicyclic Hydroxy-1H-pyrrolopyridine-trione Containing HIV-1 Integrase Inhibitors

HIV-1 integrase (IN) is a validated therapeutic target for the treatment of AIDS. However, the emergence of resistance to Raltegravir, the sole marketed FDA-approved IN inhibitor, emphasizes the need to develop second-generation inhibitors that retain efficacy against clinically-relevant IN mutants....

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Chem Biol Drug Des
Autors principals: Zhao, Xue Zhi, Maddali, Kasthuraiah, Metifiot, Mathieu, Smith, Steven J., Vu, B. Christie, Marchand, Christophe, Hughes, Stephen H., Pommier, Yves, Burke, Terrence R.
Format: Artigo
Idioma:Inglês
Publicat: 2011
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6385889/
https://ncbi.nlm.nih.gov/pubmed/22107736
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1747-0285.2011.01270.x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars